Updates are available Correction dated 2023-08-21
Click to view Correction: https://doi.org/10.1186/s13195-023-01284-9
-
Authors
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM109025)
National Institute of Neurological Disorders and Stroke (U01NS093334)
National Institute on Aging (R01AG053798)
- License Information
-
More Information
Article History
Received: 28 May 2020
Accepted: 29 July 2020
First Online: 17 August 2020
Change Date: 21 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13195-023-01284-9
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: JC has provided consultation to Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Bracket, Cassava, Cerecin, Cerevel, Cognoptix, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, Green Valley, Grifols, Hisun, Karuna, Novo Nordisk, Nutricia, Otsuka, ReMYND, Resverlogix, Roche, Samumed, Samus, Signant Health, Sunovion, Suven, Third Rock, and United Neuroscience pharmaceutical and assessment companies. JC has stock options in ADAMAS, MedAvante, QR pharma, BiOasis, and United Neuroscience. JC owns the copyright of the Neuropsychiatric Inventory. Dr. Cummings is supported by Keep Memory Alive (KMA); NIGMS grant P20GM109025; NINDS grant U01NS093334; and NIA grant R01AG053798. JB and GL have no disclosures.
